|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Restoration of LASP1 expression in miR-377-3p-overexpressing cells attenuated the inhibition of glioma cell malignancy and reversed the dephosphorylation of AKT.
|
30372896 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells.
|
31214505 |
2019 |
|
Glioma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
SAE1 overexpression induces an increase of the SUMOylation and Ser473 phosphorylation of AKT, which promotes glioma cell growth in vitro and in nude mouse tumor model.
|
31345225 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SIL1 functions as an oncogene in glioma by AKT/mTOR signaling pathway.
|
29997438 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of Akt1 inhibited the growth and invasion of glioma cells by decreasing phosphorylated Akt, β-catenin, phosphorylated Foxo1 and Cyclin D1 and inducing the expression of Foxo1, which was consistent with the effect of miR-637 overexpression.
|
25597410 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of microRNA-708 promotes cell growth and epithelial-to-mesenchymal transition by activating the SPHK2/AKT/β-catenin pathway in glioma.
|
31171769 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our data firstly demonstrated that CREB1-induced FOXD2-AS1 contributed to glioma progression by upregulating AKT1 via competitively binding to miR-185, providing a novel strategy for targeting FOXD2-AS1 as a potential biomarker and a therapeutic target in glioma patients.
|
30553445 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our research indicated a MEG3-miR-93-PI3K-AKT pathway in regulating the growth of glioma, providing a promising therapy for glioma.
|
28791407 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicated that combined treatment of <sup>125</sup>I seeds and SAL achieved enhanced growth inhibition and apoptosis in human glioma in vitro and in vivo through triggering ROS-mediated DNA damage and regulation of MAPKs and AKT pathways, which validated that the combined strategy of using <sup>125</sup>I seeds and SAL could be a highly efficient way to achieve enhanced glioma chemo-radiotherapy.
|
29804240 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serine/threonine-protein kinase PFTAIRE 1 (PFTK1) is a member of the cyclin‑dependent kinase family that is highly expressed in several malignant tumors, including hepatocellular carcinoma, esophageal, breast and gastric cancers, and glioma.
|
28498444 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The circ-CFH/miR-149/AKT1 regulation axis may be a potential target for glioma therapy.
|
30111766 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The current results also indicted that YKL-40 plays a pivotal role in glioma cell proliferation through activation of the MAPK and AKT pathways.
|
20499402 |
2010 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of Akt1 protein and mRNA was similar in glioma and normal control tissues.
|
20167810 |
2010 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
LHGDN |
The initial characterization of SH-6 included treatment of glioma cells with increasing doses of SH-6 (0.30-30 microM) and examining the effects on AKT signaling proteins by Western blot analyses and in kinase assays with immunoprecipitated AKT1.
|
17041888 |
2006 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The initial characterization of SH-6 included treatment of glioma cells with increasing doses of SH-6 (0.30-30 microM) and examining the effects on AKT signaling proteins by Western blot analyses and in kinase assays with immunoprecipitated AKT1.
|
17041888 |
2006 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The newly identified miR-92a/KLF4/AKT/mTOR axis provides novel insight into the pathogenesis of glioma.
|
31378903 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The RAS/RAF mitogen-activated protein kinase pathway (MAPK) is highly active in many tumor types including the majority of high-grade gliomas and expression of activated RAS or RAF in neural progenitor cells combined with either AKT activation or Ink4a/Arf loss leads to the development of high-grade gliomas in vivo.
|
21057530 |
2011 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The upregulation of miR‑342 inactivated the AKT and ERK pathways in glioma.
|
28677773 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapy based on AKT inhibition may complement currently available treatment to control glioma cell invasion.
|
15557754 |
2005 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that sevoflurane inhibits glioma cell migration and invasion and that these beneficial effects are mediated by the upregulation of miRNA‑637, which suppresses Akt1 expression and activity.
|
27840895 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting the PI3K/AKT/mTOR pathway.
|
25351348 |
2015 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This RTK/PTEN/PI3K pathway leads to activated AKT and phospho-AKT levels are elevated in the majority of GBM tumor samples and cell lines, which studies show help glioma cells grow uncontrolled, evade apoptosis, and enhance tumor invasion.
|
21827416 |
2011 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the present study demonstrated that Src plays a biologically significant role in tumor proliferation and apoptosis and enhances the cytotoxic effect of temozolomide through AKT supression in glioma.
|
23338526 |
2013 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data indicate that IL-17 can promote the proliferation and migration of glioma cells via PI3K/Akt1/NF-κB-p65 activation, and these findings might provide a new insight into glioma pathogenesis.
|
30660646 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGFR2 inhibitor SU-1498, AKT inhibitor LY294002 and FAK inhibitor 14 (FAK inhibitor) blocked the Robo4 knockdown-mediated alteration in glioma angiogenesis in vitro.
|
25833462 |
2015 |